Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bedoradrine - Kissei Pharmaceutical/MediciNova

Drug Profile

Bedoradrine - Kissei Pharmaceutical/MediciNova

Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; MediciNova
  • Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute asthma

Highest Development Phases

  • Phase II Acute asthma; Preterm labour
  • No development reported Chronic obstructive pulmonary disease; Status asthmaticus

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in USA (IV, Infusion)
  • 09 Feb 2018 Phase-II clinical trials in Preterm labour in USA (IV) before February 2018 (Kissei pipeline, February 2018)
  • 07 Feb 2018 Bedoradrine is available for licensing as of 12 Feb 2018. www.medicinova.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top